自由基硒磺酰化研究进展
收稿日期: 2025-10-23
修回日期: 2025-11-29
网络出版日期: 2026-02-02
基金资助
山东省自然科学基金(ZR2022QB233)
国家自然科学基金(21876062)
Research Progress on Radical Selenosulfonylation
Received date: 2025-10-23
Revised date: 2025-11-29
Online published: 2026-02-02
Supported by
Natural Science Foundation of Shandong Province(ZR2022QB233)
National Natural Science Foundation of China(21876062)
Copyright
硒磺酰化已成为同时构建C—Se和C—S键最为快速和实用的方法之一, 该转化制备的硒代砜类化合物不仅在药物研发、天然产物结构单元修饰及功能材料中占据重要地位, 而且能作为通用的合成中间体实现进一步转化. 自由基硒磺酰化具有反应活性高、条件温和及官能团耐受性优良等特点, 近二十年来取得了蓬勃发展. 从磺酰化试剂的种类出发, 将该领域细分为来源于硒磺酸酯、磺酰肼、亚磺酸钠/亚磺酸、芳基重氮盐与1,4-二氮杂双环[2.2.2]辛烷-1,4-二鎓-1,4-二亚磺酸(DABSO)结合、环丁酮肟酯与DABSO结合以及炔烃与DABSO结合, 简要论述了近年来自由基硒磺酰化反应的研究进展.
刘世峥 , 窦明煜 , 崔玉 , 窦建民 , 魏文廷 . 自由基硒磺酰化研究进展[J]. 有机化学, 2026 , 46(4) : 1621 -1634 . DOI: 10.6023/cjoc202510020
Selenosulfonylation has emerged as one of the most efficient and practical methods for the simultaneous construction of C—Se and C—S bonds. The selenosulfone compounds prepared by this transformation not only play significant roles in drug development, natural product structural modification, and functional materials, but also serve as versatile synthetic intermediates for further transformations. Over the past two decades, radical selenosulfonylation has experienced considerable progress, characterized by its high reactivity, mild reaction conditions, and excellent functional group tolerance. The recent advances in radical selenosulfonation systematically categorized based on the types of sulfonylation reagents employed, including those derived from selenosulfonate salt, sulfonylhydrazine, sodium sulfite or sulfinic acid, aryl diazonium salt combined with 1,4-diazabicyclo[2.2.2]octane-1,4-diium-1,4-disulfinate (DABSO), cyclobutanone oxime ester combined with DABSO, and alkyne combined with DABSO. A concise overview of the recent developments in this field is provided accordingly.
| [1] |
(a)
(b)
(c)
(d)
(王薪, 张艳, 孙凯, 孟建萍, 张冰, 有机化学, 2021, 41, 4588.)
|
| [2] |
(a)
(b)
(c)
|
| [3] |
|
| [4] |
(a)
(b)
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
(a)
(b)
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
(a)
(b)
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
(a)
(b)
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
/
| 〈 |
|
〉 |